Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15735460 | 0.85 | THRB (0.48) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL2132334 | 0.85 | MEN1 (0.52) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL15733276 | 0.84 | NAPEPLD (0.47) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL15733146 | 0.84 | THRB (0.49) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL15735333 | 0.83 | THRB (0.47) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL15733200 | 0.83 | KDM4E (0.48) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL2130234 | 0.80 | MEN1 (0.49) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL2129573 | 0.79 | MEN1 (0.52) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL2131731 | 0.79 | MEN1 (0.52) | NAPEPLDTHRBMEN1KMT2ALMNA | |
| SCHEMBL2131202 | 0.79 | MEN1 (0.52) | NAPEPLDTHRBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925316-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-10-07 | — | — | EP | claimed |
| WO-2014082739-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-06-05 | — | — | WO | claimed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2925316-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014082739-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ1, KCNQ2 | NAPEPLD 869/4885THRB 1687/4885MEN1 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.